Globe Newswire03.22.19
Shockwave Medical, a developer and commercializer of Intravascular Lithotripsy to treat complex calcified cardiovascular disease, has appointed Laura Francis to its Board of Directors to chair the Audit Committee.
Francis currently serves as chief financial officer (CFO) of SI-BONE Inc.. Prior to joining SI-BONE, Francis was CFO at Auxogyn Inc., a women’s health company; Promega Corporation, a life science reagent company; and Bruker BioSciences Corporation, a public life science instrumentation company. Francis has also served as chief operating officer and CFO of Nutra-Park Inc., and as CFO of Hypercosm Inc., a software company. Earlier in her career, Francis was an engagement manager with McKinsey & Company and an audit manager with Coopers & Lybrand.
Francis earned a B.B.A. from the University of Wisconsin and an M.B.A. from Stanford University. She is a certified public accountant (inactive) in California.
Shockwave Medical develops and commercializes products intended to transform the way calcified cardiovascular disease is treated. Shockwave Medical aims to establish a new standard of care for medical device treatment of atherosclerotic cardiovascular disease through its differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque.
Francis currently serves as chief financial officer (CFO) of SI-BONE Inc.. Prior to joining SI-BONE, Francis was CFO at Auxogyn Inc., a women’s health company; Promega Corporation, a life science reagent company; and Bruker BioSciences Corporation, a public life science instrumentation company. Francis has also served as chief operating officer and CFO of Nutra-Park Inc., and as CFO of Hypercosm Inc., a software company. Earlier in her career, Francis was an engagement manager with McKinsey & Company and an audit manager with Coopers & Lybrand.
Francis earned a B.B.A. from the University of Wisconsin and an M.B.A. from Stanford University. She is a certified public accountant (inactive) in California.
Shockwave Medical develops and commercializes products intended to transform the way calcified cardiovascular disease is treated. Shockwave Medical aims to establish a new standard of care for medical device treatment of atherosclerotic cardiovascular disease through its differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque.